Corautus Genetics Merges With VIA Following VEGF-2 Gene Therapy Failure
This article was originally published in The Pink Sheet Daily
Executive Summary
Principal focus of the newly formed company will be VIA’s cardiovascular pipeline, VIA exec tells “The Pink Sheet” DAILY.
You may also be interested in...
Corautus To Pursue Future Studies Of VEGF-2 Angina Therapy Following Lift Of Clinical Hold
Firm asserts adverse events in the Phase IIb GENASIS of patients with severe angina were not caused by the gene therapy.
Asia Spotlight: Ascendancy Healthcare CEO Sandy Zweifach On The Gap In China
Seeing a gap between the large infrastructure being built in China by multinational and domestic companies, Ascendancy hopes to be an interface to help China access drugs from the West.
Ascendancy Healthcare CEO Sandy Zweifach On The Gap In China: An Interview With PharmAsia News (Part 2 of 2)
Seeing a gap between the large infrastructure being built in China by multinational and domestic companies, Ascendancy hopes to be an interface to help China access drugs from the West.